register

News & Trends - Biotechnology

Biotech companies and investment risk – new study

Health Industry Hub | January 13, 2021 |

Biotech News: Contrary to public perception, investing in biotech companies may not entail higher risk than investing in non-biotech companies, according to a new report.

Researchers studied the financial performance of 319 biotechnology companies focused on developing therapeutic products that completed Initial public offerings (IPOs) from 1997-2016.

When it came to companies that eventually had their stocks delisted, there was no statistically significant difference between biotech companies and firms in the control group. In both cases, the most common reason for delisting was a merger or an acquisition.

With respect to acquisitions, more biotech companies with a market capitalisation of greater than $1 billion were acquired compared to non-biotech companies.

According to the study, bankruptcy or liquidation was not common in either group (3.1% for biotech and 2.5% for control). There was also no difference between groups for the interval between IPO and delisting. Overall, this indicates that biotech and control companies had similar rates of success and failures.

“Despite the extraordinary performance of the biotech sector in recent years, biotech is still often portrayed as a high-risk investment. Our study suggests that, in fact, the high-risk, high-return pattern associated with biotech companies after their IPO is a common characteristic of companies completing IPOs from other sectors as well,” said Dr. Fred Ledley, Director of the Centre for Integration of Science and Industry “This study also suggests that, for these emerging, public companies, the science-based, biotech business model generates equivalent economic value to more traditional, revenue-based business models.”

The authors noted that caution should be used in interpreting these findings, as most biotech companies with products in development were acquired before the end of the study period and most revenue from these products would not have been accrued until after acquisition. Thus, the revenues were not recognised in their analysis.

According to the study, a measure of company success in the biotechnology sector is less likely to be based on sustained revenues or profits, but rather acquisition.


News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms

Health Industry Hub | April 17, 2025 |

Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]

More


News & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Oncologists pioneer liquid biopsy-guided treatment in lung cancer

Health Industry Hub | April 17, 2025 |

Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]

More


Medical and Science

The high cost of record low research funding

The high cost of record low research funding

Health Industry Hub | April 17, 2025 |

Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]

More


News & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor

UCB secures dermatology indication with first dual IL-17A/F inhibitor

Health Industry Hub | April 17, 2025 |

UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]

More


This content is copyright protected. Please subscribe to gain access.